1
|
Andrade MCR, Lemos BRP, Silva LM, Pecotte JK. Eliminating Potential Effects of Other Infections During Selection of Nonhuman Primates for COVID-19 Research. Comp Med 2023; 73:45-57. [PMID: 36744555 PMCID: PMC9948906 DOI: 10.30802/aalas-cm-21-000086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The study of nonhuman primates (NHP) can provide significant insights into our understanding numerous infectious agents. The etiological agent of COVID-19, SARS-CoV-2 virus, first emerged in 2019 and has so far been responsible for the deaths of over 4 million people globally. In the frenzied search to understand its pathogenesis and immunology and to find measures for prevention and control of this pandemic disease, NHP, particularly macaques, are the preferred model because they manifest similar clinical signs and immunologic features as humans. However, possible latent, subclinical, and opportunistic infections not previously detected in animals participating in a study may obscure experimental results and confound data interpretations in testing treatments and vaccine studies for COVID-19. Certain pathophysiologic changes that occur with SARS-CoV-2 virus infection are similar to those of simian pathogens. The current review discusses numerous coinfections of COVID-19 with other diseases and describes possible outcomes and mechanisms in COVID-19 studies of NHP that have coinfections. Due to the urgency triggered by the pandemic, screening that is more rigorous than usual is necessary to limit background noise and maximize the reliability of data from NHP COVID-19 studies. Screening for influenza virus, selected respiratory bacteria, and regional endemic pathogens such as vector-borne agents, together with the animal's individual exposure history, should be the main considerations in selecting a NHP for a COVID-19 study. In addition, because NHP are susceptible to the SARS-CoV-2 virus, management and surveillance measures should be established to prevent transmission to healthy animals from infected colony animals and husbandry staff. This review presents compiled data on the use of NHP in COVID-19 studies, emphasizing the need to create the most reliable NHP model for those studies by extensive screening for other pathogens.
Collapse
Key Words
- absl, animal biosafety level
- ace-2, angiotensin-converting enzyme
- ards, acute respiratory distress syndrome
- cnprc, california national primate research center
- e, envelope
- esr, erythrocyte sedimentation rate
- hav, hepatitis a virus
- hbv, hepatitis b virus
- hgf hepatocyte growth factor
- htlv, human t-cell lymphotropic virus
- ifn, interferon
- il, interleukin
- ip, inducible protein
- m, matrix
- mcp, monocyte chemotactic proteins
- mcsf, macrophage colony-stimulating factor
- mip, macrophage inflammatory protein
- n, nucleocapsid
- nsp, non-structural proteins
- rdrp, rna-dependent rna polymerase
- s, spike
- sars-cov-2, severe acute respiratory syndrome-coronavirus-2
- sfv, simian foamy virus
- sop, standard operating procedures
- srv/d, simian retrovirus type d
- stlv, simian t-lymphotropic virus
- tb, tuberculosis
- tgf, transforming growth factor
- tmprss2 transmembrane serine protease 2
Collapse
Affiliation(s)
- Marcia C R Andrade
- Institute of Science and Technology on Biomodels, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil;,
| | - Bárbara R P Lemos
- Institute of Science and Technology on Biomodels, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Larissa M Silva
- Institute of Science and Technology on Biomodels, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; University of Grande Rio, Duque de Caxias, Brazil
| | | |
Collapse
|
2
|
Yee JL, Grant R, Haertel AJ, Allers C, Carpenter AB, Van Rompay KKA, Roberts JA. Multi-site proficiency testing for validation and standardization of assays to detect specific pathogen-free viruses, coronaviruses, and other agents in nonhuman primates. J Med Primatol 2022; 51:234-245. [PMID: 35426147 PMCID: PMC9851150 DOI: 10.1111/jmp.12586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 03/14/2022] [Accepted: 04/06/2022] [Indexed: 01/21/2023]
Abstract
In efforts to increase rigor and reproducibility, the USA National Primate Research Centers (NPRCs) have focused on qualification of reagents, cross-laboratory validations, and proficiency testing for methods to detect infectious agents and accompanying immune responses in nonhuman primates. The pathogen detection working group, comprised of laboratory scientists, colony managers, and leaders from the NPRCs, has championed the effort to produce testing that is reliable and consistent across laboratories. Through multi-year efforts with shared proficiency samples, testing percent agreement has increased from as low as 67.1% for SRV testing in 2010 to 92.1% in 2019. The 2019 average agreement for the four basic SPF agents improved to >96% (86.5% BV, 98.9 SIV, 92.1 SRV, and 97.0 STLV). As new pathogens such as SARS coronavirus type 2 emerge, these steps can now be quickly replicated to develop and implement new assays that ensure rigor, reproducibly, and quality for NHP pathogen detection.
Collapse
Affiliation(s)
- JoAnn L. Yee
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, CA
| | - Richard Grant
- Primate Pathogen Detection Services Laboratory, Washington National Primate Research Center, University of Washington, Seattle, WA
| | - Andrew J. Haertel
- Oregon National Primate Research Center, Oregon Health Science University, Beaverton, OR
| | - Carolina Allers
- Pathogen Detection and Quantification Core, Tulane National Primate Research Center, Tulane University, Covington, LA
| | - Amanda B. Carpenter
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, CA
| | - Koen K. A. Van Rompay
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, CA,Department of Pathology, Microbiology & Immunology, School of Veterinary Medicine, University of California, Davis , CA
| | - Jeffrey A. Roberts
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, CA,Department of Medicine & Epidemiology, School of Veterinary Medicine, University of California, Davis, CA
| |
Collapse
|
3
|
Yee J, Carpenter A, Nham P, Halley B, Van Rompay KKA, Roberts J. Developing and validating SARS-CoV-2 assays for nonhuman primate surveillance. J Med Primatol 2022; 51:264-269. [PMID: 35794847 PMCID: PMC9350325 DOI: 10.1111/jmp.12604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 06/09/2022] [Accepted: 06/24/2022] [Indexed: 11/28/2022]
Abstract
Introduction In early 2020, the California National Primate Research Center implemented surveillance to address the threat of SARS‐CoV‐2 infection in its nonhuman primate colony. Materials/Methods To detect antiviral antibodies, multi‐antigen assays were developed and validated on enzyme immunoassay and multiplex microbead immunofluorescent assay (MMIA) platforms. To detect viral RNA, RT‐PCR was also performed. Results/Conclusion Using a 4plex, antibody was identified in 16/16 experimentally infected animals; and specificity for spike, nucleocapsid, receptor binding domain, and whole virus antigens was 95.2%, 93.8%, 94.3%, and 97.1%, respectively on surveillance samples. Six laboratories compared this MMIA favorably with nine additional laboratory‐developed or commercially available assays. Using a screen and confirm algorithm, 141 of the last 2441 surveillance samples were screen‐reactive requiring confirmatory testing. Although 35 samples were reactive to either nucleocapsid or spike; none were reactive to both. Over 20 000 animals have been tested and no spontaneous infections have so far been confirmed across the NIH sponsored National Primate Research Centers.
Collapse
Affiliation(s)
- JoAnn Yee
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, Davis, California, USA
| | - Amanda Carpenter
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, Davis, California, USA
| | - Peter Nham
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, Davis, California, USA
| | - Bryson Halley
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, Davis, California, USA
| | - Koen K A Van Rompay
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, Davis, California, USA.,Department of Pathology, Microbiology & Immunology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
| | - Jeffrey Roberts
- Primate Assay Laboratory, California National Primate Research Center, University of California, Davis, Davis, California, USA.,Department Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
| |
Collapse
|
4
|
Deere JD, Carroll TD, Dutra J, Fritts L, Sammak RL, Yee JL, Olstad KJ, Reader JR, Kistler A, Kamm J, Di Germanio C, Shaan Lakshmanappa Y, Elizaldi SR, Roh JW, Simmons G, Watanabe J, Pollard RE, Usachenko J, Immareddy R, Schmidt BA, O’Connor SL, DeRisi J, Busch MP, Iyer SS, Van Rompay KKA, Hartigan-O’Connor DJ, Miller CJ. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma. Microbiol Spectr 2021; 9:e0139721. [PMID: 34817208 PMCID: PMC8612156 DOI: 10.1128/spectrum.01397-21] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 10/22/2021] [Indexed: 12/15/2022] Open
Abstract
Human clinical studies investigating use of convalescent plasma (CP) for treatment of coronavirus disease 2019 (COVID-19) have produced conflicting results. Outcomes in these studies may vary at least partly due to different timing of CP administration relative to symptom onset. The mechanisms of action of CP include neutralizing antibodies but may extend beyond virus neutralization to include normalization of blood clotting and dampening of inflammation. Unresolved questions include the minimum therapeutic titer in the CP units or CP recipient as well as the optimal timing of administration. Here, we show that treatment of macaques with CP within 24 h of infection does not reduce viral shedding in nasal or lung secretions compared to controls and does not detectably improve any clinical endpoint. We also demonstrate that CP administration does not impact viral sequence diversity in vivo, although the selection of a viral sequence variant in both macaques receiving normal human plasma was suggestive of immune pressure. Our results suggest that CP, administered to medium titers, has limited efficacy, even when given very early after infection. Our findings also contribute information important for the continued development of the nonhuman primate model of COVID-19. These results should inform interpretation of clinical studies of CP in addition to providing insights useful for developing other passive immunotherapies and vaccine strategies. IMPORTANCE Antiviral treatment options for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain very limited. One treatment that was explored beginning early in the pandemic (and that is likely to be tested early in future pandemics) is plasma collected from people who have recovered from coronavirus disease 2019 (COVID-19), known as convalescent plasma (CP). We tested if CP reduces viral shedding or disease in a nonhuman primate model. Our results demonstrate that administration of CP 1 day after SARS-CoV-2 infection had no significant impact on viral loads, clinical disease, or sequence diversity, although treatment with normal human plasma resulted in selection of a specific viral variant. Our results demonstrate that passive immunization with CP, even during early infection, provided no significant benefit in a nonhuman primate model of SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Jesse D. Deere
- Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, California, USA
| | - Timothy D. Carroll
- Center for Immunology and Infectious Diseases, University of California Davis, Davis, California, USA
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - Joseph Dutra
- Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, California, USA
| | - Linda Fritts
- Center for Immunology and Infectious Diseases, University of California Davis, Davis, California, USA
| | - Rebecca Lee Sammak
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - JoAnn L. Yee
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - Katherine J. Olstad
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - J. Rachel Reader
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - Amy Kistler
- Chan Zuckerberg Biohub, San Francisco, California, USA
| | - Jack Kamm
- Chan Zuckerberg Biohub, San Francisco, California, USA
| | | | | | - Sonny R. Elizaldi
- Center for Immunology and Infectious Diseases, University of California Davis, Davis, California, USA
| | - Jamin W. Roh
- Center for Immunology and Infectious Diseases, University of California Davis, Davis, California, USA
| | - Graham Simmons
- Vitalant Research Institute, San Francisco, California, USA
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
| | - Jennifer Watanabe
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - Rachel E. Pollard
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - Jodie Usachenko
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - Ramya Immareddy
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - Brian A. Schmidt
- Center for Immunology and Infectious Diseases, University of California Davis, Davis, California, USA
| | - Shelby L. O’Connor
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Joseph DeRisi
- Chan Zuckerberg Biohub, San Francisco, California, USA
- Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, USA
| | - Michael P. Busch
- Vitalant Research Institute, San Francisco, California, USA
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
| | - Smita S. Iyer
- Center for Immunology and Infectious Diseases, University of California Davis, Davis, California, USA
- California National Primate Research Center, University of California Davis, Davis, California, USA
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, USA
| | - Koen K. A. Van Rompay
- California National Primate Research Center, University of California Davis, Davis, California, USA
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, USA
| | - Dennis J. Hartigan-O’Connor
- Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, California, USA
- California National Primate Research Center, University of California Davis, Davis, California, USA
| | - Christopher J. Miller
- Center for Immunology and Infectious Diseases, University of California Davis, Davis, California, USA
- California National Primate Research Center, University of California Davis, Davis, California, USA
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, USA
- Department of Internal Medicine, Division of Infectious Diseases, School of Medicine, University of California Davis, Davis, California, USA
| |
Collapse
|
5
|
Alleva DG, Delpero AR, Scully MM, Murikipudi S, Ragupathy R, Greaves EK, Sathiyaseelan T, Haworth JR, Shah NJ, Rao V, Nagre S, Lancaster TM, Webb SS, Jasa AI, Ronca SE, Green FM, Elyard HA, Yee J, Klein J, Karnes L, Sollie F, Zion TC. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine 2021; 39:6601-6613. [PMID: 34642088 PMCID: PMC8491978 DOI: 10.1016/j.vaccine.2021.09.077] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 09/29/2021] [Accepted: 09/30/2021] [Indexed: 12/12/2022]
Abstract
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain.
Collapse
Affiliation(s)
- David G Alleva
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Andrea R Delpero
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Melanie M Scully
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Sylaja Murikipudi
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Ramya Ragupathy
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Emma K Greaves
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | | | - Jeffrey R Haworth
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Nishit J Shah
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Vidhya Rao
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Shashikant Nagre
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Thomas M Lancaster
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States
| | - Sarah S Webb
- Biomere Biomedical Research Models, 57 Union St., Worcester, MA 01608, United States
| | - Allison I Jasa
- Biomere Biomedical Research Models, 57 Union St., Worcester, MA 01608, United States
| | - Shannon E Ronca
- Feigin ABSL-3 Facility, Baylor, College of Medicine, 1102 Bates Ave, 300.15, Houston, TX 77030, United States
| | - Freedom M Green
- Feigin ABSL-3 Facility, Baylor, College of Medicine, 1102 Bates Ave, 300.15, Houston, TX 77030, United States
| | - Hanne Andersen Elyard
- BIOQUAL, Inc., 9600 Medical Center Drive, Suite 101, Rockville, MD 20850-3336, United States
| | - JoAnn Yee
- Primate Assay Laboratory, CA National Primate Research Center, University of California, Davis, CA 95616, United States
| | - Jeffrey Klein
- Sinclair Research Center, 562 State Road DD, Auxvasse, MO 65231, United States
| | - Larry Karnes
- Sinclair Research Center, 562 State Road DD, Auxvasse, MO 65231, United States
| | - Frans Sollie
- Pharmaceutical Research Associates Group B.V., Amerikaweg 18, 9407 TK Assen, Netherlands
| | - Todd C Zion
- Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States.
| |
Collapse
|
6
|
|
7
|
Abstract
COVID-19, the disease caused by the SARS-CoV-2 betacoronavirus, was declared a pandemic by the World Health Organization on March 11, 2020. Since then, SARS-CoV-2 has triggered a devastating global health and economic emergency. In response, a broad range of preclinical animal models have been used to identify effective therapies and vaccines. Current animal models do not express the full spectrum of human COVID-19 disease and pathology, with most exhibiting mild to moderate disease without mortality. NHPs are physiologically, genetically, and immunologically more closely related to humans than other animal species; thus, they provide a relevant model for SARS-CoV-2 investigations. This overview summarizes NHP models of SARS-CoV-2 and their role in vaccine and therapeutic development.
Collapse
Key Words
- ace2, angiotensin l converting enzyme 2
- ade, antibody dependent enhancement
- agm, african green monkey
- ards, acute respiratory distress syndrome
- balf, bronchoalveolar lavage fluid
- cj, conjunctival
- cm, cynomolgus macaque
- covid-19, coronavirus disease 19
- cp, convalescent plasma
- dad, diffuse alveolar damage
- dpc, days post challenge
- dpi, days post infection
- ggos, ground glass opacities
- grna, genomic ribonucleic acid
- hcq, hydroxychloroquine
- it, intratracheal
- nab, neutralizing antibodies
- ptm, pigtail macaque
- rbd, receptor binding domain
- rm, rhesus macaque
- s, spike
- sgrna, subgenomic ribonucleic acid
- th1, type 1 t helper cell
- vrna, viral ribonucleic acid
Collapse
Affiliation(s)
- Anita M Trichel
- Division of Laboratory Animal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| |
Collapse
|
8
|
Hild SA, Chang MC, Murphy SJ, Grieder FB. Nonhuman primate models for SARS-CoV-2 research: Infrastructure needs for pandemic preparedness. Lab Anim (NY) 2021; 50:140-141. [PMID: 33927412 DOI: 10.1038/s41684-021-00760-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- Sheri Ann Hild
- Office of Research Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA.
| | - Michael C Chang
- Office of Research Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA
| | - Stephanie J Murphy
- Office of Research Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA
| | - Franziska B Grieder
- Office of Research Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
9
|
Shaan Lakshmanappa Y, Elizaldi SR, Roh JW, Schmidt BA, Carroll TD, Weaver KD, Smith JC, Verma A, Deere JD, Dutra J, Stone M, Franz S, Sammak RL, Olstad KJ, Rachel Reader J, Ma ZM, Nguyen NK, Watanabe J, Usachenko J, Immareddy R, Yee JL, Weiskopf D, Sette A, Hartigan-O'Connor D, McSorley SJ, Morrison JH, Tran NK, Simmons G, Busch MP, Kozlowski PA, Van Rompay KKA, Miller CJ, Iyer SS. SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nat Commun 2021; 12:541. [PMID: 33483492 PMCID: PMC7822826 DOI: 10.1038/s41467-020-20642-x] [Citation(s) in RCA: 64] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Accepted: 12/08/2020] [Indexed: 12/28/2022] Open
Abstract
CD4 T follicular helper (Tfh) cells are important for the generation of durable and specific humoral protection against viral infections. The degree to which SARS-CoV-2 infection generates Tfh cells and stimulates the germinal center (GC) response is an important question as we investigate vaccine induced immunity against COVID-19. Here, we report that SARS-CoV-2 infection in rhesus macaques, either infused with convalescent plasma, normal plasma, or receiving no infusion, resulted in transient accumulation of pro-inflammatory monocytes and proliferating Tfh cells with a Th1 profile in peripheral blood. CD4 helper cell responses skewed predominantly toward a Th1 response in blood, lung, and lymph nodes. SARS-CoV-2 Infection induced GC Tfh cells specific for the SARS-CoV-2 spike and nucleocapsid proteins, and a corresponding early appearance of antiviral serum IgG antibodies. Collectively, the data show induction of GC responses in a rhesus model of mild COVID-19.
Collapse
Affiliation(s)
| | - Sonny R Elizaldi
- Center for Immunology and Infectious Diseases, UC Davis, Davis, CA, USA
- Graduate Group in Immunology, UC Davis, Davis, CA, USA
| | - Jamin W Roh
- Center for Immunology and Infectious Diseases, UC Davis, Davis, CA, USA
- Graduate Group in Immunology, UC Davis, Davis, CA, USA
| | - Brian A Schmidt
- Center for Immunology and Infectious Diseases, UC Davis, Davis, CA, USA
| | - Timothy D Carroll
- California National Primate Research Center, UC Davis, Davis, CA, USA
| | - Kourtney D Weaver
- Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| | - Justin C Smith
- Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| | - Anil Verma
- Center for Immunology and Infectious Diseases, UC Davis, Davis, CA, USA
| | - Jesse D Deere
- California National Primate Research Center, UC Davis, Davis, CA, USA
| | - Joseph Dutra
- California National Primate Research Center, UC Davis, Davis, CA, USA
| | - Mars Stone
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Vitalant Research Institute, San Francisco, CA, USA
| | - Sergej Franz
- Vitalant Research Institute, San Francisco, CA, USA
| | | | | | - J Rachel Reader
- California National Primate Research Center, UC Davis, Davis, CA, USA
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, UC Davis, Davis, CA, USA
| | - Zhong-Min Ma
- California National Primate Research Center, UC Davis, Davis, CA, USA
| | - Nancy K Nguyen
- Center for Immunology and Infectious Diseases, UC Davis, Davis, CA, USA
| | - Jennifer Watanabe
- California National Primate Research Center, UC Davis, Davis, CA, USA
| | - Jodie Usachenko
- California National Primate Research Center, UC Davis, Davis, CA, USA
| | - Ramya Immareddy
- California National Primate Research Center, UC Davis, Davis, CA, USA
| | - JoAnn L Yee
- California National Primate Research Center, UC Davis, Davis, CA, USA
| | - Daniela Weiskopf
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA
| | - Alessandro Sette
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA
- Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, La Jolla, San Diego, CA, USA
| | - Dennis Hartigan-O'Connor
- California National Primate Research Center, UC Davis, Davis, CA, USA
- Department of Medical Microbiology and Immunology, School of Medicine, UC Davis, Davis, CA, USA
| | - Stephen J McSorley
- Center for Immunology and Infectious Diseases, UC Davis, Davis, CA, USA
- Department of Anatomy, Physiology, and Cell Biology, School of Veterinary Medicine, UC Davis, Davis, CA, USA
| | - John H Morrison
- California National Primate Research Center, UC Davis, Davis, CA, USA
- Department of Neurology, School of Medicine, UC Davis, Davis, CA, USA
| | - Nam K Tran
- Pathology and Laboratory Medicine, School of Medicine, UC Davis, Davis, CA, USA
| | - Graham Simmons
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Vitalant Research Institute, San Francisco, CA, USA
| | - Michael P Busch
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- Vitalant Research Institute, San Francisco, CA, USA
| | - Pamela A Kozlowski
- Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| | - Koen K A Van Rompay
- California National Primate Research Center, UC Davis, Davis, CA, USA.
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, UC Davis, Davis, CA, USA.
| | - Christopher J Miller
- Center for Immunology and Infectious Diseases, UC Davis, Davis, CA, USA.
- California National Primate Research Center, UC Davis, Davis, CA, USA.
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, UC Davis, Davis, CA, USA.
| | - Smita S Iyer
- Center for Immunology and Infectious Diseases, UC Davis, Davis, CA, USA.
- California National Primate Research Center, UC Davis, Davis, CA, USA.
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, UC Davis, Davis, CA, USA.
| |
Collapse
|
10
|
Yee JL, Van Rompay KKA, Carpenter AB, Nham PB, Halley BM, Iyer SS, Hartigan‐O'Connor DJ, Miller CJ, Roberts JA. SARS-CoV-2 surveillance for a non-human primate breeding research facility. J Med Primatol 2020; 49:322-331. [PMID: 32621339 PMCID: PMC7361642 DOI: 10.1111/jmp.12483] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 06/06/2020] [Accepted: 06/08/2020] [Indexed: 01/06/2023]
Abstract
BACKGROUND The emergence of SARS-CoV-2 and the ensuing COVID-19 pandemic prompted the need for a surveillance program to determine the viral status of the California National Primate Research Center non-human primate breeding colony, both for reasons of maintaining colony health and minimizing the risk of interference in COVID-19 and other research studies. METHODS We collected biological samples from 10% of the rhesus macaque population for systematic testing to detect SARS-CoV-2 virus by RT-PCR and host antibody response by ELISA. Testing required the development and validation of new assays and an algorithm using in laboratory-developed and commercially available reagents and protocols. RESULTS AND CONCLUSIONS No SARS-CoV-2 RNA or antibody was detected in this study; therefore, we have proposed a modified testing algorithm for sentinel surveillance to monitor for any future transmissions. As additional reagents and controls become available, assay development and validation will continue, leading to the enhanced sensitivity, specificity, accuracy, and efficiency of testing.
Collapse
Affiliation(s)
- JoAnn L. Yee
- Primate Assay LaboratoryCalifornia National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
| | - Koen K. A. Van Rompay
- Primate Assay LaboratoryCalifornia National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
- Pathology, Microbiology and ImmunologySchool of Veterinary MedicineUniversity of CaliforniaDavisCaliforniaUSA
| | - Amanda B. Carpenter
- Primate Assay LaboratoryCalifornia National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
| | - Peter B. Nham
- Primate Assay LaboratoryCalifornia National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
| | - Bryson M. Halley
- Primate Assay LaboratoryCalifornia National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
| | - Smita S. Iyer
- Pathology, Microbiology and ImmunologySchool of Veterinary MedicineUniversity of CaliforniaDavisCaliforniaUSA
- Center for Immunology and Infectious DiseasesUniversity of CaliforniaDavisCaliforniaUSA
| | | | - Christopher J. Miller
- Pathology, Microbiology and ImmunologySchool of Veterinary MedicineUniversity of CaliforniaDavisCaliforniaUSA
- Center for Immunology and Infectious DiseasesUniversity of CaliforniaDavisCaliforniaUSA
| | - Jeffrey A. Roberts
- Primate Assay LaboratoryCalifornia National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
- Medicine and EpidemiologySchool of Veterinary MedicineUniversity of CaliforniaDavisCaliforniaUSA
| |
Collapse
|
11
|
Elizaldi S, Lakshmanappa YS, Roh J, Schmidt B, Carroll T, Weaver K, Smith J, Deere J, Dutra J, Stone M, Franz S, Sammak R, Olstad K, Reader JR, Ma ZM, Nguyen N, Watanabe J, Usachenko J, Immareddy R, Yee J, Weiskopf D, Sette A, Hartigan-O'Connor D, McSorley S, Morrison J, Tran N, Simmons G, Busch M, Kozlowsk P, van Rompay K, Miller C, Iyer S. SARS-CoV-2 infection induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Res Sq 2020:rs.3.rs-51545. [PMID: 32818217 PMCID: PMC7430596 DOI: 10.21203/rs.3.rs-51545/v1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
CD4 T follicular helper (T fh ) cells are important for the generation of durable and specific humoral protection against viral infections. The degree to which SARS-CoV-2 infection generates T fh cells and stimulates the germinal center response is an important question as we investigate vaccine options for the current pandemic. Here we report that SARS-CoV-2 infection resulted in transient accumulation of pro-inflammatory monocytes and proliferating T fh cells with a T h 1 profile in peripheral blood. CD4 helper cell responses were skewed predominantly toward a T h 1 response in blood, lung, and lymph nodes. We observed the generation of germinal center T fh cells specific for the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins, and a corresponding early appearance of antiviral serum IgG antibodies. Our data suggest that a vaccine promoting T h 1-type T fh responses that target the S protein may lead to protective immunity.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Justin Smith
- Louisiana State University Health Sciences Center
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Daniela Weiskopf
- Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA
| | | | | | | | | | | | | | | | - Pamela Kozlowsk
- Louisiana State University Health Sciences Center New Orleans
| | | | | | - Smita Iyer
- University of California Davis School of Veterinary Medicine and California National Primate Research Center
| |
Collapse
|
12
|
Elizaldi SR, Lakshmanappa YS, Roh JW, Schmidt BA, Carroll TD, Weaver KD, Smith JC, Deere JD, Dutra J, Stone M, Sammak RL, Olstad KJ, Reader JR, Ma ZM, Nguyen NK, Watanabe J, Usachaenko J, Immareddy R, Yee JL, Weiskopf D, Sette A, Hartigan-O’Connor D, McSorley SJ, Morrison JH, Tran NK, Simmons G, Busch MP, Kozlowski PA, Van Rompay KK, Miller CJ, Iyer SS. SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques. bioRxiv 2020:2020.07.07.191007. [PMID: 32676606 PMCID: PMC7359530 DOI: 10.1101/2020.07.07.191007] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
CD4 T follicular helper (T fh ) cells are important for the generation of long-lasting and specific humoral protection against viral infections. The degree to which SARS-CoV-2 infection generates T fh cells and stimulates the germinal center response is an important question as we investigate vaccine options for the current pandemic. Here we report that, following infection with SARS-CoV-2, adult rhesus macaques exhibited transient accumulation of activated, proliferating T fh cells in their peripheral blood on a transitory basis. The CD4 helper cell responses were skewed predominantly toward a T h 1 response in blood, lung, and lymph nodes, reflective of the interferon-rich cytokine environment following infection. We also observed the generation of germinal center T fh cells specific for the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins, and a corresponding early appearance of antiviral serum IgG antibodies but delayed or absent IgA antibodies. Our data suggest that a vaccine promoting Th1-type Tfh responses that target the S protein may lead to protective immunity.
Collapse
Affiliation(s)
- Sonny R. Elizaldi
- Center for Immunology and Infectious Diseases, UC Davis, CA
- Graduate Group in Immunology, UC Davis, CA
| | | | - Jamin W. Roh
- Center for Immunology and Infectious Diseases, UC Davis, CA
- Graduate Group in Immunology, UC Davis, CA
| | | | | | - Kourtney D. Weaver
- Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA
| | - Justin C. Smith
- Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA
| | - Jesse D. Deere
- California National Primate Research Center, UC Davis, CA
| | - Joseph Dutra
- California National Primate Research Center, UC Davis, CA
| | - Mars Stone
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
- Vitalant Research Institute, San Francisco, CA
| | | | | | - J. Rachel Reader
- California National Primate Research Center, UC Davis, CA
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, UC Davis, CA
| | - Zhong-Min Ma
- California National Primate Research Center, UC Davis, CA
| | | | | | | | | | - JoAnn L. Yee
- California National Primate Research Center, UC Davis, CA
| | - Daniela Weiskopf
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA
| | - Alessandro Sette
- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA
- Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA
| | - Dennis Hartigan-O’Connor
- California National Primate Research Center, UC Davis, CA
- Department of Medical Microbiology and Immunology, School of Medicine, UC Davis, CA
| | - Stephen J. McSorley
- Center for Immunology and Infectious Diseases, UC Davis, CA
- Department of Anatomy, Physiology, and Cell Biology, School of Veterinary Medicine, UC Davis, CA
| | - John H. Morrison
- California National Primate Research Center, UC Davis, CA
- Department of Neurology, School of Medicine, UC Davis, CA
| | - Nam K. Tran
- Pathology and Laboratory Medicine, School of Medicine, UC Davis, CA
| | - Graham Simmons
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
- Vitalant Research Institute, San Francisco, CA
| | - Michael P Busch
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
- Vitalant Research Institute, San Francisco, CA
| | - Pamela A. Kozlowski
- Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA
| | - Koen K.A. Van Rompay
- California National Primate Research Center, UC Davis, CA
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, UC Davis, CA
| | - Christopher J. Miller
- Center for Immunology and Infectious Diseases, UC Davis, CA
- California National Primate Research Center, UC Davis, CA
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, UC Davis, CA
| | - Smita S. Iyer
- Center for Immunology and Infectious Diseases, UC Davis, CA
- California National Primate Research Center, UC Davis, CA
- Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, UC Davis, CA
| |
Collapse
|